1
|
Gil JV, Miralles A, de las Heras S, Such E, Avetisyan G, Díaz-González Á, Santiago M, Fuentes C, Fernández JM, Lloret P, Navarro I, Montesinos P, Llop M, Barragán E. Comprehensive detection of CRLF2 alterations in acute lymphoblastic leukemia: a rapid and accurate novel approach. Front Mol Biosci 2024; 11:1362081. [PMID: 38370004 PMCID: PMC10869515 DOI: 10.3389/fmolb.2024.1362081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2023] [Accepted: 01/22/2024] [Indexed: 02/20/2024] Open
Abstract
Introduction: Acute lymphoblastic leukemia (ALL) is a prevalent childhood cancer with high cure rate, but poses a significant medical challenge in adults and relapsed patients. Philadelphia-like acute lymphoblastic leukemia (Ph-like ALL) is a high-risk subtype, with approximately half of cases characterized by CRLF2 overexpression and frequent concomitant IKZF1 deletions. Methods: To address the need for efficient, rapid, and cost-effective detection of CRLF2 alterations, we developed a novel RT-qPCR technique combining SYBR Green and highresolution melting analysis on a single plate. Results: The method successfully identified CRLF2 expression, P2RY8::CRLF2 fusions, and CRLF2 and JAK2 variants, achieving a 100% sensitivity and specificity. Application of this method across 61 samples revealed that 24.59% exhibited CRLF2 overexpression, predominantly driven by IGH::CRLF2 (73.33%). High Resolution Melting analysis unveiled concurrent CRLF2 or JAK2 variants in 8.19% of samples, as well as a dynamic nature of CRLF2 alterations during disease progression. Discussion: Overall, this approach provides an accurate identification of CRLF2 alterations, enabling improved diagnostic and facilitating therapeutic decision-making.
Collapse
Affiliation(s)
- José Vicente Gil
- Accredited Research Group on Hematology, Instituto de Investigación Sanitaria la Fe, Valencia, Spain
| | - Alberto Miralles
- Accredited Research Group on Hematology, Instituto de Investigación Sanitaria la Fe, Valencia, Spain
| | - Sandra de las Heras
- Accredited Research Group on Hematology, Instituto de Investigación Sanitaria la Fe, Valencia, Spain
| | - Esperanza Such
- Accredited Research Group on Hematology, Instituto de Investigación Sanitaria la Fe, Valencia, Spain
- Hematology Service, Hospital Universitario y Politécnico la Fe, Valencia, Spain
- Centro de Investigación Biomédica en Red de Cáncer, CIBERONC CB16/12/00284, Instituto de Salud Carlos III, Madrid, Spain
| | - Gayane Avetisyan
- Accredited Research Group on Hematology, Instituto de Investigación Sanitaria la Fe, Valencia, Spain
| | - Álvaro Díaz-González
- Accredited Research Group on Hematology, Instituto de Investigación Sanitaria la Fe, Valencia, Spain
| | - Marta Santiago
- Accredited Research Group on Hematology, Instituto de Investigación Sanitaria la Fe, Valencia, Spain
| | - Carolina Fuentes
- Accredited Research Group on Clinical and Translational Cancer Research, Instituto de Investigación Sanitaria la Fe, Valencia, Spain
- Onco-Hematology Unit, Pediatrics Service, Hospital Universitario y Politécnico la Fe, Valencia, Spain
| | - José María Fernández
- Accredited Research Group on Clinical and Translational Cancer Research, Instituto de Investigación Sanitaria la Fe, Valencia, Spain
- Onco-Hematology Unit, Pediatrics Service, Hospital Universitario y Politécnico la Fe, Valencia, Spain
| | - Pilar Lloret
- Accredited Research Group on Hematology, Instituto de Investigación Sanitaria la Fe, Valencia, Spain
- Hematology Service, Hospital Universitario y Politécnico la Fe, Valencia, Spain
| | - Irene Navarro
- Accredited Research Group on Hematology, Instituto de Investigación Sanitaria la Fe, Valencia, Spain
- Hematology Service, Hospital Universitario y Politécnico la Fe, Valencia, Spain
| | - Pau Montesinos
- Accredited Research Group on Hematology, Instituto de Investigación Sanitaria la Fe, Valencia, Spain
- Hematology Service, Hospital Universitario y Politécnico la Fe, Valencia, Spain
| | - Marta Llop
- Accredited Research Group on Hematology, Instituto de Investigación Sanitaria la Fe, Valencia, Spain
- Centro de Investigación Biomédica en Red de Cáncer, CIBERONC CB16/12/00284, Instituto de Salud Carlos III, Madrid, Spain
- Molecular Biology Unit, Clinical Analysis Service, Hospital Universitario y Politécnico la Fe, Valencia, Spain
| | - Eva Barragán
- Accredited Research Group on Hematology, Instituto de Investigación Sanitaria la Fe, Valencia, Spain
- Centro de Investigación Biomédica en Red de Cáncer, CIBERONC CB16/12/00284, Instituto de Salud Carlos III, Madrid, Spain
- Molecular Biology Unit, Clinical Analysis Service, Hospital Universitario y Politécnico la Fe, Valencia, Spain
| |
Collapse
|
2
|
Galán V, Beléndez C, Echecopar C, Estival P, Sissini L, Olivas R, Bueno D, Molina B, Fuentes C, Regueiro A, Benítez I, Plaza M, Margarit A, Rifón J, Pascual A, Palomo P, Urtasun A, Fuster JL, Díaz de Heredia C, Fernández Navarro JM, González-Vicent M, Ruz B, Pérez-Martínez A. Treosulfan-Based Conditioning Regimen In Pediatric Hematopoietic Stem Cell Transplantation: A Retrospective Analysis on Behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC). Transplant Cell Ther 2023; 29:702.e1-702.e11. [PMID: 37595686 DOI: 10.1016/j.jtct.2023.08.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2023] [Revised: 07/24/2023] [Accepted: 08/13/2023] [Indexed: 08/20/2023]
Abstract
Increasing data on treosulfan-based conditioning regimens before hematopoietic stem cell transplantation (HSCT) demonstrate the consistent benefits of this approach, particularly regarding acute toxicity. This study aimed to describe the results of treosulfan-based conditioning regimens in children, focusing on toxicity and outcomes when used to treat both malignant and nonmalignant diseases. This retrospective observational study of pediatric patients treated in Spain with treosulfan-based conditioning regimens before HSCT was based on data collection from electronic clinical records. We studied a total of 160 treosulfan-based conditioning HSCTs to treat nonmalignant diseases (n = 117) or malignant diseases (n = 43) in 158 children and adolescents. The median patient age at HSCT was 5.1 years (interquartile range, 2 to 10 years). The most frequent diagnoses were primary immunodeficiency (n = 42; 36%) and sickle cell disease (n = 42; 36%) in the nonmalignant disease cohort and acute lymphoblastic leukemia (n = 15; 35%) in the malignant disease cohort. Engraftment occurred in 97% of the patients. The median times to neutrophil engraftment (17 days versus 14 days; P = .008) and platelet engraftment (20 days versus 15 days; P = .002) were linger in the nonmalignant cohort. The 1-year cumulative incidence of veno-occlusive disease was 7.98% (95% confidence interval [CI], 4.6% to 13.6%), with no significant differences between cohorts. The 1-year cumulative incidence of grade III-IV acute graft-versus-host disease (GVHD) was higher in the malignant disease cohort (18% versus 3.2%; P = .011). Overall, the malignant cohort had both a higher total incidence (9% versus 3%; P < .001) and a higher 2-year cumulative incidence (16% versus 1.9%; P < .001) of total chronic GVHD. The 2-year cumulative transplantation-related mortality was 15%, with no difference between the 2 cohorts. The 5-year overall survival was 80% (95% CI, 72% to 86%) and was higher in the nonmalignant cohort (87% versus 61%; P = .01). The 2-year cumulative incidence of relapse was 25% in the malignant cohort. The 5-year cumulative GVHD-free, relapse-free survival rate was 60% (95% CI, 51% to 70%) and was higher in the nonmalignant cohort (72% versus 22%; P < .001). A treosulfan-based radiation-free conditioning regimen is feasible, achieving a high engraftment rate and 5-year overall survival, and is an emerging option for the first HSCT in nonmalignant diseases.
Collapse
Affiliation(s)
- Victor Galán
- Pediatric Hemato-Oncology, La Paz University Hospital, idiPAZ Research Institute, Madrid, Spain; Pediatric Hemato-Oncology, La Paz University Hospital, Madrid, Spain
| | | | - Carlos Echecopar
- Pediatric Hemato-Oncology, La Paz University Hospital, Madrid, Spain
| | | | - Luisa Sissini
- Pediatric Hemato-Oncology, La Paz University Hospital, idiPAZ Research Institute, Madrid, Spain
| | | | - David Bueno
- Pediatric Hemato-Oncology, La Paz University Hospital, idiPAZ Research Institute, Madrid, Spain; Pediatric Hemato-Oncology, La Paz University Hospital, Madrid, Spain
| | - Blanca Molina
- Pediatric Hemato-Oncology, Hospital Niño Jesus, Madrid, Spain
| | | | - Alexandra Regueiro
- Pediatric Hemato-Oncology, University of Santiago Clinical Hospital, Santiago de Compostela, Spain
| | - Isabel Benítez
- Pediatric Hemato-Oncology, Hospital Vall d'Hebron, Barcelona, Spain
| | - Mercedes Plaza
- Pediatric Hemato-Oncology, Virgen de la Arrixaca University Clinical Hospital, Biomedical Research Institute of Murcia (IMIB), El Palmar, Spain
| | - Adriana Margarit
- Pediatric Hemato-Oncology, Hospital Sant Joan de Déu, Barcelona, Spain
| | - José Rifón
- Clínica Universitaria de Navarra, Pamplona, Spain
| | - Antonia Pascual
- Pediatric Hemato-Oncology, Hospital Carlos Haya, Málaga, Spain
| | | | - Andrea Urtasun
- Pediatric Hemato-Oncology, Hospital Sant Joan de Déu, Barcelona, Spain
| | - José Luis Fuster
- Pediatric Hemato-Oncology, Virgen de la Arrixaca University Clinical Hospital, Biomedical Research Institute of Murcia (IMIB), El Palmar, Spain
| | | | | | | | - Beatriz Ruz
- La Paz University Hospital, Institute of Medical and Molecular Genetics (INGEMM), idiPAZ Research Institute, Madrid, Spain
| | - Antonio Pérez-Martínez
- Pediatric Hemato-Oncology, La Paz University Hospital, idiPAZ Research Institute, Madrid, Spain; Pediatric Hemato-Oncology, La Paz University Hospital, Madrid, Spain; Pediatric Hemato-Oncology, La Paz University Hospital, idiPAZ Research Institute, Pediatric Department, Autonomous University of Madrid, Madrid, Spain.
| |
Collapse
|
3
|
Moreno C, Ramos-Elbal E, Velasco P, Aguilar Y, Gonzáález Martínez B, Fuentes C, Molinos Á, Guerra-García P, Palomo P, Verdu J, Adán Pedroso RM, Vagace JM, López-Duarte M, Regueiro A, Tasso M, Dapena JL, Salinas JA, Navarro S, Bautista F, Lassaletta Á, Lendínez F, Rives S, Pascual A, Rodríguez A, Pérez-Hurtado JM, Fernández JM, Pérez-Martínez A, González-Vicent M, Díaz de Heredia C, Fuster JL. Haploidentical vs. HLA-matched donor hematopoietic stem-cell transplantation for pediatric patients with acute lymphoblastic leukemia in second remission: A collaborative retrospective study of the Spanish Group for Bone Marrow Transplantation in Children (GETMON/GETH) and the Spanish Childhood Relapsed ALL Board (ReALLNet). Front Pediatr 2023; 11:1140637. [PMID: 37020654 PMCID: PMC10067875 DOI: 10.3389/fped.2023.1140637] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/09/2023] [Accepted: 02/23/2023] [Indexed: 04/07/2023] Open
Abstract
Introduction Studies addressing the role of haploidentical as alternative to HLA-matched donors for stem cell transplantation (SCT) often include patients with diverse hematological malignancies in different remission statuses. Methods We compared outcomes of children with acute lymphoblastic leukemia (ALL) undergoing SCT in second complete remission (CR2) from haploidentical (n = 25) versus HLA-matched donor (n = 51). Results Patients were equally distributed across both groups according to age, immunophenotype, time to and site of relapse, relapse risk-group allocation, and minimal residual disease (MRD) before SCT. Incidence of graft failure, acute graft versus host disease (GVHD), and other early complications did not differ between both groups. We found no differences in overall survival (58.7% versus 59.5%; p = .8), leukemia free survival (LFS) (48% versus 36.4%; p = .5), event free survival (40% versus 34.4%; p = .69), cumulative incidence (CI) of subsequent relapse (28% versus 40.9%; p = .69), treatment related mortality (24% versus 23.6%; p = .83), CI of cGVHD (4.5% versus 18.7%; p = .2), and chronic GVHD-free and leukemia-free survival (44% versus 26.3%; p = .3) after haploidentical donor SCT. Chronic GVHD (HR = 0.09; p=.02) had protective impact, and MRD ≥ 0.01% before SCT (HR = 2.59; p=.01) had unfavorable impact on LFS. Discussion These results support the role of haploidentical donor SCT in children with ALL in CR2.
Collapse
Affiliation(s)
- Celia Moreno
- Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain
| | | | - Pablo Velasco
- Hospital Universitario Vall d’Hebron, Vall d’Hebron Institut de Recerca, Barcelona, Spain
| | | | - Berta Gonzáález Martínez
- Hospital Universitario La Paz, IdiPAZ, Instituto de Investigación, Hospital Universitario La Paz, Madrid, Spain
| | | | | | - Pilar Guerra-García
- Hospital Universitario La Paz, IdiPAZ, Instituto de Investigación, Hospital Universitario La Paz, Madrid, Spain
- Hospital Universitario 12 de octubre, Madrid, Spain
| | - Pilar Palomo
- Hospital Universitario Central de Asturias, Oviedo, Spain
| | - Jaime Verdu
- Hospital Universitario de Valencia, Valencia, Spain
| | | | | | - Mónica López-Duarte
- Hospital de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, IDIVAL, Santander, Spain
| | - Alexandra Regueiro
- Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain
| | - María Tasso
- Hospital General Universitario Doctor Balmis, Alicante, Spain
| | - José Luis Dapena
- Pediatric Cancer Center, Hospital Sant Joan de Déu, Barcelona, Spain
- Institut de Recerca San Joan de Déu,Barcelona, Spain
| | | | - Samuel Navarro
- Hospital Universitario Son Espases, Palma de Mallorca, Spain
| | | | | | | | - Susana Rives
- Pediatric Cancer Center, Hospital Sant Joan de Déu, Barcelona, Spain
- Institut de Recerca San Joan de Déu,Barcelona, Spain
| | | | | | | | | | - Antonio Pérez-Martínez
- Hospital Universitario La Paz, IdiPAZ, Instituto de Investigación, Hospital Universitario La Paz, Madrid, Spain
| | | | | | - José Luis Fuster
- Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain
- Instituto Murciano de Investigación Biosanitaria (IMIB), Murcia, Spain
- Correspondence: José Luis Fuster
| |
Collapse
|
4
|
Marcié S, Gerard JP, Dejean C, Feuillade J, Gautier M, Montagné L, Fuentes C, Hannoun-Levi JM. The inverse square law: A basic principle in brachytherapy. Cancer Radiother 2022; 26:1075-1077. [PMID: 35843781 DOI: 10.1016/j.canrad.2022.04.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2022] [Accepted: 04/02/2022] [Indexed: 11/28/2022]
Abstract
The purpose of this article is to remind the importance of the inverse square law in radiotherapy and especially in brachytherapy. Indeed, beyond the impact in radiation therapy with high energy beam, there is the use of radionuclides and low energy photons with short FSD where it is still more important. Comparisons between Iridium Brachytherapy and low energy X-rays brachytherapy show equivalent dose distributions in the first few centimeters. If the inverse square law is not the only element influencing the dose distributions calculations, it must not be forgotten. And it is playing a major role in brachytherapy with short FSD (<6cm).
Collapse
Affiliation(s)
- S Marcié
- Radiotherapy Department, centre Antoine-Lacassagne, 33, avenue Valombrose, 06189 Nice cedex2, France
| | - J P Gerard
- Radiotherapy Department, centre Antoine-Lacassagne, 33, avenue Valombrose, 06189 Nice cedex2, France.
| | - C Dejean
- Radiotherapy Department, centre Antoine-Lacassagne, 33, avenue Valombrose, 06189 Nice cedex2, France
| | - J Feuillade
- Radiotherapy Department, centre Antoine-Lacassagne, 33, avenue Valombrose, 06189 Nice cedex2, France
| | - M Gautier
- Radiotherapy Department, centre Antoine-Lacassagne, 33, avenue Valombrose, 06189 Nice cedex2, France
| | - L Montagné
- Radiotherapy Department, centre Antoine-Lacassagne, 33, avenue Valombrose, 06189 Nice cedex2, France
| | - C Fuentes
- Hospital Nuestra Senora-de-Candelaria, Tenerife, Spain
| | - J M Hannoun-Levi
- Radiotherapy Department, centre Antoine-Lacassagne, 33, avenue Valombrose, 06189 Nice cedex2, France
| |
Collapse
|
5
|
Makkar S, Béguin M, Dissertori G, Flock J, Fuentes C, Gajewski J, Hrbacek J, McNamara K, Ritzer C, Rucinski A, Weber D, Lomax A, Winterhalter C. PO-1602 Image reconstruction using the PETITION PET scanner aimed at biologically guided proton therapy. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)03566-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
6
|
Fernández-Vera F, Urrutia DC, Rossel PO, Herskovic V, Fuentes C. Social+Me: a persuasive application to increase communication between students and their support networks in Southern Chile. PeerJ Comput Sci 2022; 8:e848. [PMID: 35174268 PMCID: PMC8802782 DOI: 10.7717/peerj-cs.848] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2021] [Accepted: 12/16/2021] [Indexed: 06/14/2023]
Abstract
Technology can improve university students' communication, helping them maintain relationships. Although there are many available technological tools, students face challenges-e.g., living far from home, failing grades, depression-that may isolate them from their networks. Most research into these topics has been conducted in countries in which students leave their parents' home while at university, which is not the case for most students in southern Chile. In this context that has been seldom studied, this paper presents two studies, focusing on two research questions: (1) How do university students in southern Chile communicate? (2) Can a mobile application persuade university students to increase their communication patterns? To answer these questions, we conducted a survey with 90 students in southern Chile, and then developed a persuasive application called Social+Me, aimed at monitoring communication with students' support networks and persuading them to keep in touch. We conducted a preliminary evaluation of Social+Me, and the application was well received by participants, who felt that it improved their communication with their social network. The main impact of our study lies in applying persuasive technologies to the communicative practice of university students to prevent students from feeling isolated or unsupported.
Collapse
Affiliation(s)
- Fabián Fernández-Vera
- Department of Computer Science, Universidad Católica de la Santísima Concepción, Concepción, Chile
| | - Denisse C. Urrutia
- Department of Computer Science, Universidad Católica de la Santísima Concepción, Concepción, Chile
| | - Pedro O. Rossel
- Department of Computer Science, Universidad Católica de la Santísima Concepción, Concepción, Chile
- Centro de Investigación en Biodiversidad y Ambientes Sustentables (CIBAS), Universidad Católica de la Santísima Concepción, Concepción, Chile
| | - Valeria Herskovic
- Department of Computer Science, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Carolina Fuentes
- School of Computer Science and Informatics, Cardiff University, Cardiff, United Kingdom
| |
Collapse
|
7
|
Borgert CJ, Fuentes C, Burgoon LD. Principles of dose-setting in toxicology studies: the importance of kinetics for ensuring human safety. Arch Toxicol 2021; 95:3651-3664. [PMID: 34623454 PMCID: PMC8536606 DOI: 10.1007/s00204-021-03155-4] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2021] [Accepted: 09/02/2021] [Indexed: 01/11/2023]
Abstract
Regulatory toxicology seeks to ensure that exposures to chemicals encountered in the environment, in the workplace, or in products pose no significant hazards and produce no harm to humans or other organisms, i.e., that chemicals are used safely. The most practical and direct means of ensuring that hazards and harms are avoided is to identify the doses and conditions under which chemical toxicity does not occur so that chemical concentrations and exposures can be appropriately limited. Modern advancements in pharmacology and toxicology have revealed that the rates and mechanisms by which organisms absorb, distribute, metabolize and eliminate chemicals-i.e., the field of kinetics-often determine the doses and conditions under which hazard, and harm, are absent, i.e., the safe dose range. Since kinetics, like chemical hazard and toxicity, are extensive properties that depend on the amount of the chemical encountered, it is possible to identify the maximum dose under which organisms can efficiently metabolize and eliminate the chemicals to which they are exposed, a dose that has been referred to as the kinetic maximum dose, or KMD. This review explains the rationale that compels regulatory toxicology to embrace the advancements made possible by kinetics, why understanding the kinetic relationship between the blood level produced and the administered dose of a chemical is essential for identifying the safe dose range, and why dose-setting in regulatory toxicology studies should be informed by estimates of the KMD rather than rely on the flawed concept of maximum-tolerated toxic dose, or MTD.
Collapse
Affiliation(s)
- C J Borgert
- Applied Pharmacology and Toxicology, Inc., Gainesville, FL, USA.
- Center for Environmental and Human Toxicology (CEHT), Department of Physiological Sciences, University of Florida College of Veterinary Medicine, Gainesville, FL, USA.
| | - C Fuentes
- Department of Statistics, Oregon State University, Corvallis, OR, USA
| | | |
Collapse
|
8
|
Gargallo P, Oltra S, Yáñez Y, Juan-Ribelles A, Calabria I, Segura V, Lázaro M, Balaguer J, Tormo T, Dolz S, Fernández JM, Fuentes C, Torres B, Andrés M, Tasso M, Castel V, Font de Mora J, Cañete A. Germline Predisposition to Pediatric Cancer, from Next Generation Sequencing to Medical Care. Cancers (Basel) 2021; 13:5339. [PMID: 34771502 PMCID: PMC8582391 DOI: 10.3390/cancers13215339] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2021] [Revised: 10/18/2021] [Accepted: 10/21/2021] [Indexed: 11/16/2022] Open
Abstract
Knowledge about genetic predisposition to pediatric cancer is constantly expanding. The categorization and clinical management of the best-known syndromes has been refined over the years. Meanwhile, new genes for pediatric cancer susceptibility are discovered every year. Our current work shares the results of genetically studying the germline of 170 pediatric patients diagnosed with cancer. Patients were prospectively recruited and studied using a custom panel, OncoNano V2. The well-categorized predisposing syndromes incidence was 9.4%. Likely pathogenic variants for predisposition to the patient's tumor were identified in an additional 5.9% of cases. Additionally, a high number of pathogenic variants associated with recessive diseases was detected, which required family genetic counseling as well. The clinical utility of the Jongmans MC tool was evaluated, showing a high sensitivity for detecting the best-known predisposing syndromes. Our study confirms that the Jongmans MC tool is appropriate for a rapid assessment of patients; however, the updated version of Ripperger T criteria would be more accurate. Meaningfully, based on our findings, up to 9.4% of patients would present genetic alterations predisposing to cancer. Notably, up to 20% of all patients carry germline pathogenic or likely pathogenic variants in genes related to cancer and, thereby, they also require expert genetic counseling. The most important consideration is that the detection rate of genetic causality outside Jongmans MC et al. criteria was very low.
Collapse
Affiliation(s)
- Pablo Gargallo
- Pediatric Oncology Department, Hospital Universitario y Politécnico La Fe de Valencia, 46026 Valencia, Spain; (Y.Y.); (A.J.-R.); (V.S.); (J.B.); (T.T.); (J.M.F.); (C.F.); (B.T.); (M.A.); (V.C.); (A.C.)
- Imegen–Health in Code Group, Department of Oncology, Paterna, 46980 Valencia, Spain; (I.C.); (M.L.)
| | - Silvestre Oltra
- Genetics Unit, Hospital Universitario y Politécnico La Fe de Valencia, 46026 Valencia, Spain;
- Genetics Department, Universidad de Valencia, 46010 Valencia, Spain
| | - Yania Yáñez
- Pediatric Oncology Department, Hospital Universitario y Politécnico La Fe de Valencia, 46026 Valencia, Spain; (Y.Y.); (A.J.-R.); (V.S.); (J.B.); (T.T.); (J.M.F.); (C.F.); (B.T.); (M.A.); (V.C.); (A.C.)
| | - Antonio Juan-Ribelles
- Pediatric Oncology Department, Hospital Universitario y Politécnico La Fe de Valencia, 46026 Valencia, Spain; (Y.Y.); (A.J.-R.); (V.S.); (J.B.); (T.T.); (J.M.F.); (C.F.); (B.T.); (M.A.); (V.C.); (A.C.)
| | - Inés Calabria
- Imegen–Health in Code Group, Department of Oncology, Paterna, 46980 Valencia, Spain; (I.C.); (M.L.)
| | - Vanessa Segura
- Pediatric Oncology Department, Hospital Universitario y Politécnico La Fe de Valencia, 46026 Valencia, Spain; (Y.Y.); (A.J.-R.); (V.S.); (J.B.); (T.T.); (J.M.F.); (C.F.); (B.T.); (M.A.); (V.C.); (A.C.)
| | - Marián Lázaro
- Imegen–Health in Code Group, Department of Oncology, Paterna, 46980 Valencia, Spain; (I.C.); (M.L.)
| | - Julia Balaguer
- Pediatric Oncology Department, Hospital Universitario y Politécnico La Fe de Valencia, 46026 Valencia, Spain; (Y.Y.); (A.J.-R.); (V.S.); (J.B.); (T.T.); (J.M.F.); (C.F.); (B.T.); (M.A.); (V.C.); (A.C.)
| | - Teresa Tormo
- Pediatric Oncology Department, Hospital Universitario y Politécnico La Fe de Valencia, 46026 Valencia, Spain; (Y.Y.); (A.J.-R.); (V.S.); (J.B.); (T.T.); (J.M.F.); (C.F.); (B.T.); (M.A.); (V.C.); (A.C.)
| | - Sandra Dolz
- Laboratory of Cellular and Molecular Biology, Clinical and Translational Research in Cancer, Instituto de Investigación Sanitaria La Fe, 46026 Valencia, Spain; (S.D.); (J.F.d.M.)
| | - José María Fernández
- Pediatric Oncology Department, Hospital Universitario y Politécnico La Fe de Valencia, 46026 Valencia, Spain; (Y.Y.); (A.J.-R.); (V.S.); (J.B.); (T.T.); (J.M.F.); (C.F.); (B.T.); (M.A.); (V.C.); (A.C.)
| | - Carolina Fuentes
- Pediatric Oncology Department, Hospital Universitario y Politécnico La Fe de Valencia, 46026 Valencia, Spain; (Y.Y.); (A.J.-R.); (V.S.); (J.B.); (T.T.); (J.M.F.); (C.F.); (B.T.); (M.A.); (V.C.); (A.C.)
| | - Bárbara Torres
- Pediatric Oncology Department, Hospital Universitario y Politécnico La Fe de Valencia, 46026 Valencia, Spain; (Y.Y.); (A.J.-R.); (V.S.); (J.B.); (T.T.); (J.M.F.); (C.F.); (B.T.); (M.A.); (V.C.); (A.C.)
| | - Mara Andrés
- Pediatric Oncology Department, Hospital Universitario y Politécnico La Fe de Valencia, 46026 Valencia, Spain; (Y.Y.); (A.J.-R.); (V.S.); (J.B.); (T.T.); (J.M.F.); (C.F.); (B.T.); (M.A.); (V.C.); (A.C.)
| | - María Tasso
- Pediatric Oncology Department, Hospital General de Alicante, 03010 Alicante, Spain;
| | - Victoria Castel
- Pediatric Oncology Department, Hospital Universitario y Politécnico La Fe de Valencia, 46026 Valencia, Spain; (Y.Y.); (A.J.-R.); (V.S.); (J.B.); (T.T.); (J.M.F.); (C.F.); (B.T.); (M.A.); (V.C.); (A.C.)
| | - Jaime Font de Mora
- Laboratory of Cellular and Molecular Biology, Clinical and Translational Research in Cancer, Instituto de Investigación Sanitaria La Fe, 46026 Valencia, Spain; (S.D.); (J.F.d.M.)
| | - Adela Cañete
- Pediatric Oncology Department, Hospital Universitario y Politécnico La Fe de Valencia, 46026 Valencia, Spain; (Y.Y.); (A.J.-R.); (V.S.); (J.B.); (T.T.); (J.M.F.); (C.F.); (B.T.); (M.A.); (V.C.); (A.C.)
- Department of Pediatrics, Obstetrics and Gynecology, University of Valencia, 46010 Valencia, Spain
| |
Collapse
|
9
|
Martinez-Peromingo J, Castañeda A, Muñana A, Baeza ME, de Peralta P, Fuentes C, Barba R. Acute care for elderly patients in a functional impairment prevention unit. Rev Clin Esp 2020; 220:548-552. [PMID: 31780072 DOI: 10.1016/j.rce.2019.10.004] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2019] [Revised: 10/09/2019] [Accepted: 10/10/2019] [Indexed: 11/30/2022]
Abstract
AIM To determine whether the care of patients with moderate dependency who were hospitalised in a functional impairment prevention unit (FIPU) was superior to that of a conventional unit (CU) in terms of functional impairment and mean stay. METHODS We conducted a single-centre, retrospective, controlled intervention study that compared acute treatment in an FIPU and in conventional wards. The study included 466 elderly patients with moderate dependence (Barthel index, 30-70) and older than 75 years. Of these, 280 were included in the intervention group and 186 in the control group. The primary outcomes were loss of functionality attributable to the hospitalisation (measured by the loss of ambulation and urinary continence) and differences in the length of stay. RESULTS The patients hospitalised in the FIPU showed less functional impairment as determined by the loss of urinary continence (2.1% of the FIPU patients vs. 9.7% of the CU patients; p<.01) and the loss of walking ability (2.1% vs. 25.3%; p<.01). The patients hospitalised in the FIPU had a shorter mean stay (7.4 vs. 8.5 days; p<.05), with 1 day less of stay than the CU patients. CONCLUSION The acute care of elderly patients with moderate dependency in an FIPU was independently associated with less functional decline and shorter stays.
Collapse
Affiliation(s)
| | - A Castañeda
- Área Médica, Hospital Universitario Rey Juan Carlos, Madrid, España
| | - A Muñana
- Área Médica, Hospital Universitario Rey Juan Carlos, Madrid, España
| | - M E Baeza
- Área Médica, Hospital Universitario Rey Juan Carlos, Madrid, España
| | - P de Peralta
- Área Médica, Hospital Universitario Rey Juan Carlos, Madrid, España
| | - C Fuentes
- Área Médica, Hospital Universitario Rey Juan Carlos, Madrid, España
| | - R Barba
- Área Médica, Hospital Universitario Rey Juan Carlos, Madrid, España.
| |
Collapse
|
10
|
Martinez-Peromingo J, Castañeda A, Muñana A, Baeza M, de Peralta P, Fuentes C, Barba R. Acute care for elderly patients in a functional impairment prevention unit. Rev Clin Esp 2020. [DOI: 10.1016/j.rceng.2019.10.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
11
|
Campos-Romero S, Herskovic V, Fuentes C, Abarca E. Perceptions on Connecting Respite Care Volunteers and Caregivers. Int J Environ Res Public Health 2020; 17:ijerph17082911. [PMID: 32340190 PMCID: PMC7215678 DOI: 10.3390/ijerph17082911] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 03/10/2020] [Revised: 04/19/2020] [Accepted: 04/20/2020] [Indexed: 11/16/2022]
Abstract
The most common requirement for informal caregivers is to experience a respite or temporary break from their caregiving routine. Some initiatives have been undertaken to provide respite care through volunteer providers. We report on a qualitative study carried out in Santiago, Chile, to learn about the willingness of potential volunteers to provide respite care for bedridden older persons, as well as their willingness to use information and communication technologies (ICT) to connect to caregivers in a low-income neighbourhood within their own geographic district. A trustworthy institution that mediates the volunteer–caregiver relationship is considered to be important by potential volunteers. Potential volunteers were found to be willing to use ICT to provide respite care, sharing basic information about themselves. However, they were also aware of the digital skill gap that may exist between them and the caregivers and were distrustful of unknown websites that could connect them to care recipients.
Collapse
Affiliation(s)
- Solange Campos-Romero
- School of Nursing, Pontificia Universidad Católica de Chile, Santiago 8940000, Chile; (S.C.-R.); (E.A.)
| | - Valeria Herskovic
- Department of Computer Science, Pontificia Universidad Católica de Chile, Santiago 8940000, Chile
- Correspondence:
| | - Carolina Fuentes
- School of Computer Science, University of Nottingham, Nottingham NG8 1BB, UK;
- School of Computer Science & Informatics, Cardiff University, Cardiff CF24 3AA, Wales, UK
| | - Esmeralda Abarca
- School of Nursing, Pontificia Universidad Católica de Chile, Santiago 8940000, Chile; (S.C.-R.); (E.A.)
| |
Collapse
|
12
|
Fuster JL, Molinos-Quintana A, Fuentes C, Fernández JM, Velasco P, Pascual T, Rives S, Dapena JL, Sisinni L, López-Godino O, Palomo P, Villa-Alcázar M, Bautista F, González-Vicent M, López-Duarte M, García-Morín M, Ramos-Elbal E, Ramírez M. Blinatumomab and inotuzumab for B cell precursor acute lymphoblastic leukaemia in children: a retrospective study from the Leukemia Working Group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP). Br J Haematol 2020; 190:764-771. [PMID: 32314348 DOI: 10.1111/bjh.16647] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2020] [Accepted: 03/16/2020] [Indexed: 12/13/2022]
Abstract
Blinatumomab and inotuzumab ozogamycin represent promising alternatives to conventional chemotherapy in acute lymphoblastic leukaemia (ALL). We analysed data from 29 children with ALL treated under compassionate use with blinatumomab, inotuzumab or both. The complete remission (CR) rate in a heavily pretreated population with overt relapse was 47·6%. At earlier stages (first/second CR), both antibodies represented a useful tool to reduce minimal residual disease, and/or avoid further toxic chemotherapy until stem cell transplantation. Six patients developed grade 3 reversible non-haematological toxicity. The 12-month overall survival and event-free survival rates were 50·8 ± 26·4% and 38·9 ± 25·3% with blinatumomab, 45·8 ± 26% and 27·5 ± 25% with inotuzumab.
Collapse
Affiliation(s)
- José L Fuster
- Pediatric Oncology and Haematology Department, Hospital Clínico Universitario Virgen de la Arrixaca, Instituto Murciano de Investigación Biosanitaria (IMIB), Murcia, Spain
| | - Agueda Molinos-Quintana
- Department of Hematology, Pediatric Hematology, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina (IBIS/CISC), Sevilla, Spain
| | - Carolina Fuentes
- Pediatric Oncology and Haematology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain
| | - José M Fernández
- Pediatric Oncology and Haematology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain
| | - Pablo Velasco
- Pediatric Oncology and Haematology Department, Hospital Universitario Vall d'Hebron, Barcelona, Spain
| | - Toñi Pascual
- Pediatric Hematology Unit, Hematology Department, Hospital Regional Universitario de Málaga, Málaga, Spain
| | - Susana Rives
- Hematology Department, Hospital San Joan de Déu, Institut de Reserca Sant Joan de Déu, Barcelona, Spain
| | - José L Dapena
- Hematology Department, Hospital San Joan de Déu, Institut de Reserca Sant Joan de Déu, Barcelona, Spain
| | - Luisa Sisinni
- Pediatric Hematology, Oncology and Hematopoietic Stem Cell Transplantation Unit, Santa Creu i Sant Pau Hospital, Barcelona, Spain
| | - Oriana López-Godino
- Hematology and Oncology Department, Centro Regional de Hemodonación, Hospital Universitario Morales Meseguer, Universidad de Murcia, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), CIBERER, Murcia, Spain
| | - Pilar Palomo
- Pediatric Hematology Unit, Hematology Department., Hospital Universitario Central de Asturias, Oviedo, Spain
| | - Marta Villa-Alcázar
- Hematology and Oncology Department, Hospital Universitario HM Montepríncipe, HM/CIOCC, Madrid, Spain
| | - Francisco Bautista
- Pediatric Oncology, Haematology and Stem Cell Transplantation Department, Hospital Niño Jesús, Madrid, Spain
| | - Marta González-Vicent
- Pediatric Oncology, Haematology and Stem Cell Transplantation Department, Hospital Niño Jesús, Madrid, Spain
| | - Mónica López-Duarte
- Pediatric Hematology Unit, Hematology Department, Hospital de Valdecilla, Santander, Spain
| | - Marina García-Morín
- Pediatric Oncology and Haematology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - Eduardo Ramos-Elbal
- Pediatric Oncology and Haematology Department, Hospital Clínico Universitario Virgen de la Arrixaca, Instituto Murciano de Investigación Biosanitaria (IMIB), Murcia, Spain
| | - Manuel Ramírez
- Pediatric Oncology, Haematology and Stem Cell Transplantation Department, Hospital Niño Jesús, Madrid, Spain
| | | |
Collapse
|
13
|
Spencer JR, Stern SA, Moore JM, Weaver HA, Singer KN, Olkin CB, Verbiscer AJ, McKinnon WB, Parker JW, Beyer RA, Keane JT, Lauer TR, Porter SB, White OL, Buratti BJ, El-Maarry MR, Lisse CM, Parker AH, Throop HB, Robbins SJ, Umurhan OM, Binzel RP, Britt DT, Buie MW, Cheng AF, Cruikshank DP, Elliott HA, Gladstone GR, Grundy WM, Hill ME, Horanyi M, Jennings DE, Kavelaars JJ, Linscott IR, McComas DJ, McNutt RL, Protopapa S, Reuter DC, Schenk PM, Showalter MR, Young LA, Zangari AM, Abedin AY, Beddingfield CB, Benecchi SD, Bernardoni E, Bierson CJ, Borncamp D, Bray VJ, Chaikin AL, Dhingra RD, Fuentes C, Fuse T, Gay PL, Gwyn SDJ, Hamilton DP, Hofgartner JD, Holman MJ, Howard AD, Howett CJA, Karoji H, Kaufmann DE, Kinczyk M, May BH, Mountain M, Pätzold M, Petit JM, Piquette MR, Reid IN, Reitsema HJ, Runyon KD, Sheppard SS, Stansberry JA, Stryk T, Tanga P, Tholen DJ, Trilling DE, Wasserman LH. The geology and geophysics of Kuiper Belt object (486958) Arrokoth. Science 2020; 367:science.aay3999. [PMID: 32054694 DOI: 10.1126/science.aay3999] [Citation(s) in RCA: 49] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2019] [Accepted: 01/27/2020] [Indexed: 11/02/2022]
Abstract
The Cold Classical Kuiper Belt, a class of small bodies in undisturbed orbits beyond Neptune, is composed of primitive objects preserving information about Solar System formation. In January 2019, the New Horizons spacecraft flew past one of these objects, the 36-kilometer-long contact binary (486958) Arrokoth (provisional designation 2014 MU69). Images from the flyby show that Arrokoth has no detectable rings, and no satellites (larger than 180 meters in diameter) within a radius of 8000 kilometers. Arrokoth has a lightly cratered, smooth surface with complex geological features, unlike those on previously visited Solar System bodies. The density of impact craters indicates the surface dates from the formation of the Solar System. The two lobes of the contact binary have closely aligned poles and equators, constraining their accretion mechanism.
Collapse
Affiliation(s)
- J R Spencer
- Southwest Research Institute, Boulder, CO 80302, USA.
| | - S A Stern
- Southwest Research Institute, Boulder, CO 80302, USA
| | - J M Moore
- NASA Ames Research Center, Moffett Field, CA 94035-1000, USA
| | - H A Weaver
- Johns Hopkins University Applied Physics Laboratory, Laurel, MD 20723, USA
| | - K N Singer
- Southwest Research Institute, Boulder, CO 80302, USA
| | - C B Olkin
- Southwest Research Institute, Boulder, CO 80302, USA
| | - A J Verbiscer
- Department of Astronomy, University of Virginia, Charlottesville, VA 22904, USA
| | - W B McKinnon
- Department of Earth and Planetary Sciences and McDonnell Center for the Space Sciences, Washington University, St. Louis, MO 63130, USA
| | - J Wm Parker
- Southwest Research Institute, Boulder, CO 80302, USA
| | - R A Beyer
- SETI Institute, Mountain View, CA 94043, USA.,NASA Ames Research Center, Moffett Field, CA 94035-1000, USA
| | - J T Keane
- Division of Geological and Planetary Sciences, California Institute of Technology, Pasadena, CA 91125, USA
| | - T R Lauer
- National Science Foundation's National Optical Infrared Astronomy Research Laboratory, Tucson, AZ 26732, USA
| | - S B Porter
- Southwest Research Institute, Boulder, CO 80302, USA
| | - O L White
- SETI Institute, Mountain View, CA 94043, USA.,NASA Ames Research Center, Moffett Field, CA 94035-1000, USA
| | - B J Buratti
- Jet Propulsion Laboratory, California Institute of Technology Pasadena, CA 91109, USA
| | - M R El-Maarry
- Department of Earth and Planetary Sciences, Birkbeck, University of London, London WC1E 7HX, UK.,University College London, Gower St, Bloomsbury, London WC1E 6BT, UK
| | - C M Lisse
- Johns Hopkins University Applied Physics Laboratory, Laurel, MD 20723, USA
| | - A H Parker
- Southwest Research Institute, Boulder, CO 80302, USA
| | - H B Throop
- Independent Consultant, Washington, D.C., USA
| | - S J Robbins
- Southwest Research Institute, Boulder, CO 80302, USA
| | - O M Umurhan
- NASA Ames Research Center, Moffett Field, CA 94035-1000, USA
| | - R P Binzel
- Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - D T Britt
- Department of Physics, University of Central Florida, Orlando, FL 32816, USA
| | - M W Buie
- Southwest Research Institute, Boulder, CO 80302, USA
| | - A F Cheng
- Johns Hopkins University Applied Physics Laboratory, Laurel, MD 20723, USA
| | - D P Cruikshank
- NASA Ames Research Center, Moffett Field, CA 94035-1000, USA
| | - H A Elliott
- Southwest Research Institute, San Antonio, TX 78238, USA
| | - G R Gladstone
- Southwest Research Institute, San Antonio, TX 78238, USA
| | - W M Grundy
- Lowell Observatory, Flagstaff, AZ 86001, USA.,Department of Astronomy and Planetary Science, Northern Arizona University, Flagstaff, AZ, 86011, USA
| | - M E Hill
- Johns Hopkins University Applied Physics Laboratory, Laurel, MD 20723, USA
| | - M Horanyi
- Laboratory for Atmospheric and Space Physics, University of Colorado, Boulder, CO 80303, USA
| | - D E Jennings
- NASA Goddard Space Flight Center, Greenbelt, MD 20771, USA
| | - J J Kavelaars
- National Research Council of Canada, Victoria, BC V9E 2E7, Canada
| | - I R Linscott
- Independent Consultant, Mountain View, CA 94043, USA
| | - D J McComas
- Department of Astrophysical Sciences, Princeton University, Princeton, NJ 08544, USA
| | - R L McNutt
- Johns Hopkins University Applied Physics Laboratory, Laurel, MD 20723, USA
| | - S Protopapa
- Southwest Research Institute, Boulder, CO 80302, USA
| | - D C Reuter
- NASA Goddard Space Flight Center, Greenbelt, MD 20771, USA
| | - P M Schenk
- Lunar and Planetary Institute, Houston, TX 77058, USA
| | | | - L A Young
- Southwest Research Institute, Boulder, CO 80302, USA
| | - A M Zangari
- Southwest Research Institute, Boulder, CO 80302, USA
| | - A Y Abedin
- National Research Council of Canada, Victoria, BC V9E 2E7, Canada
| | | | - S D Benecchi
- Planetary Science Institute, Tucson, AZ 85719, USA
| | - E Bernardoni
- Laboratory for Atmospheric and Space Physics, University of Colorado, Boulder, CO 80303, USA
| | - C J Bierson
- Earth and Planetary Science Department, University of California, Santa Cruz, CA 95064, USA
| | - D Borncamp
- Decipher Technology Studios, Alexandria, VA 22314, USA
| | - V J Bray
- Lunar and Planetary Laboratory, University of Arizona, Tucson, AZ 85721, USA
| | - A L Chaikin
- Independent Science Writer, Arlington, VT 05250, USA
| | | | - C Fuentes
- Universidad de Chile, Centro de Astrofísica y Tecnologías Afines, Santiago, Chile
| | - T Fuse
- Kashima Space Technology Center, National Institute of Information and Communications Technology, Kashima, Ibaraki 314-8501, Japan
| | - P L Gay
- Planetary Science Institute, Tucson, AZ 85719, USA
| | - S D J Gwyn
- National Research Council of Canada, Victoria, BC V9E 2E7, Canada
| | - D P Hamilton
- Department of Astronomy, University of Maryland, College Park, MD 20742, USA
| | - J D Hofgartner
- Jet Propulsion Laboratory, California Institute of Technology Pasadena, CA 91109, USA
| | - M J Holman
- Center for Astrophysics, Harvard-Smithsonian Center for Astrophysics, Cambridge, MA 02138, USA
| | - A D Howard
- Department of Environmental Sciences, University of Virginia, Charlottesville, VA 22904, USA
| | - C J A Howett
- Southwest Research Institute, Boulder, CO 80302, USA
| | - H Karoji
- National Institutes of Natural Sciences, Tokyo, Japan
| | - D E Kaufmann
- Southwest Research Institute, Boulder, CO 80302, USA
| | - M Kinczyk
- Marine, Earth, and Atmospheric Sciences, North Carolina State University, Raleigh, NC 27695, USA
| | - B H May
- Independent Collaborator, Windlesham GU20 6YW, UK
| | - M Mountain
- Association of Universities for Research in Astronomy, Washington, DC 20004, USA
| | - M Pätzold
- Rheinisches Institut für Umweltforschung an der Universität zu Köln, Cologne 50931, Germany
| | - J M Petit
- Institut Univers, Temps-fréquence, Interfaces, Nanostructures, Atmosphère et environnement, Molécules, Unité Mixte de Recherche, Centre National de la Recherche Scientifique, Universite Bourgogne Franche Comte, F-25000 Besancon, France
| | - M R Piquette
- Laboratory for Atmospheric and Space Physics, University of Colorado, Boulder, CO 80303, USA
| | - I N Reid
- Space Telescope Science Institute, Baltimore, MD 21218, USA
| | | | - K D Runyon
- Johns Hopkins University Applied Physics Laboratory, Laurel, MD 20723, USA
| | - S S Sheppard
- Department of Terrestrial Magnetism, Carnegie Institution for Science, Washington, DC 20015, USA
| | - J A Stansberry
- Space Telescope Science Institute, Baltimore, MD 21218, USA
| | - T Stryk
- Roane State Community College, Oak Ridge, TN 37830, USA
| | - P Tanga
- Université Côte d'Azur, Observatoire de la Côte d'Azur, Laboratoire Lagrange/ Centre National de la Recherche Scientifique, Unité Mixte de Recherche 7293, 06304 Nice Cedex 4, France
| | - D J Tholen
- Institute for Astronomy, University of Hawaii, Honolulu, HI 96822, USA
| | - D E Trilling
- Department of Astronomy and Planetary Science, Northern Arizona University, Flagstaff, AZ, 86011, USA
| | | |
Collapse
|
14
|
Bäumer C, Fuentes C, Janson M, Matic A, Timmermann B, Wulff J. Stereotactical fields applied in proton spot scanning mode with range shifter and collimating aperture. ACTA ACUST UNITED AC 2019; 64:155003. [DOI: 10.1088/1361-6560/ab2ae7] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
|
15
|
Eltorai AEM, Eltorai AS, Fuentes C, Durand WM, Daniels AH, Ali S. Financial Implications of Physician Specialty Choice. R I Med J (2013) 2018; 101:50-55. [PMID: 30278604] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
PURPOSE To examine the approximated financial outcomes of physicians by specialty and to determine whether these correlate with mean USMLE Step 1 scores. METHODS Specialty-specific data from the Association of American Medical Colleges Careers in Medicine website were analyzed for total length of training, mean USMLE Step 1 scores, average hours worked per week, and median clinical practice salary for physicians. Hourly wage and estimated net worth at retirement were calculated. Coefficients of determination (R2) were calculated to evaluate the relationships between hourly wage, annual salary, and estimated net worth at retirement with competitiveness as measured by USMLE Step 1 scores of matched residents. RESULTS Across all 37 specialties studied, the mean hourly wage was $136 ± $40, ranging from $78 (Geriatrics) to $249 (Neurosurgery). Mean weekly hours worked across all specialties was 54.6 ± 6.4, ranging from 43.4 (Pediatric Emergency Medicine) to 71.1 (Vascular Surgery). At retirement, the mean estimated net worth for all physicians was $4,517,600 ± $1,793,095, ranging from $1,927,779 (Child & Adolescent Psychiatry) to $8,947,885 (Neurosurgery). Step 1 scores, as a marker of specialty competiveness, correlate with specialty compensation - the strongest association was with hourly wage (R2 = 0.6678), then annual salary (R2 = 0.6424), and finally by estimated net worth at retirement (R2 = 0.6158). CONCLUSION In this study, mean Step 1 scores for each medical specialty were positively correlated with compensation, including absolute salary, hourly wage and estimated net worth at retirement.
Collapse
Affiliation(s)
| | | | | | | | - Alan H Daniels
- Department of Orthopaedic Surgery, Warren Alpert Medical School of Brown University
| | - Shihab Ali
- Department of Emergency Medicine, Warren Alpert Medical School of Brown University
| |
Collapse
|
16
|
Villalba A, Santiago M, Freiria C, Montesinos P, Gomez I, Fuentes C, Rodriguez-Veiga R, Fernandez JM, Sanz G, Sanz MA, Carpio N, Solves P. Anti-D Alloimmunization after RhD-Positive Platelet Transfusion in RhD-Negative Women under 55 Years Diagnosed with Acute Leukemia: Results of a Retrospective Study. Transfus Med Hemother 2018; 45:162-166. [PMID: 29928170 DOI: 10.1159/000488804] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2017] [Accepted: 03/26/2018] [Indexed: 01/07/2023] Open
Abstract
Background Anti-D alloimmunization can occur when platelets from RhD-positive donors are transfused to RhD-negative patients, due to red blood cell residues in the platelet concentrates. Methods Our objective was to analyze the anti-D alloimmunization rate in a selected group of women under 55 years of age diagnosed with acute leukemia over an 18-year period. We focused the analysis on RhD-negative patients who received RhD-positive platelet transfusions. Results From January 1998 to October 2016, 382 women under 55 years were diagnosed with acute leukemia. A total of 56 patients were RhD-negative, and 48 (85.7%) received RhD-positive platelets. The median number of platelet concentrates transfused per patient was 23, and 48% of all platelet transfusions were RhD-positive. The 48 RhD-negative patients received a total of 949 RhD-positive platelet concentrates. Two patients developed anti-D: a 36-year-old woman with M3 acute myeloblastic leukemia and a 52-year-old patient with a secondary acute myeloblastic leukemia. Conclusion We conclude that there is a need for agreement in the transfusion guidelines on the recommendation of anti-D alloimmunization prophylaxis. We suggest a possible benefit in favor of anti-D prophylaxis in childbearing women with acute leukemia.
Collapse
Affiliation(s)
- Ana Villalba
- Blood Bank, Hematology Service. Hospital Universitari I Politècnic La Fe, Valencia, Spain
| | - Marta Santiago
- Blood Bank, Hematology Service. Hospital Universitari I Politècnic La Fe, Valencia, Spain
| | - Carmen Freiria
- Blood Bank, Hematology Service. Hospital Universitari I Politècnic La Fe, Valencia, Spain
| | - Pau Montesinos
- Blood Bank, Hematology Service. Hospital Universitari I Politècnic La Fe, Valencia, Spain
| | - Ines Gomez
- Blood Bank, Hematology Service. Hospital Universitari I Politècnic La Fe, Valencia, Spain
| | - Carolina Fuentes
- Pediatric Hemato-Oncology Service, Hospital Universitari i Politècnic La Fe, Valencia, Spain
| | - Rebeca Rodriguez-Veiga
- Blood Bank, Hematology Service. Hospital Universitari I Politècnic La Fe, Valencia, Spain
| | - José María Fernandez
- Pediatric Hemato-Oncology Service, Hospital Universitari i Politècnic La Fe, Valencia, Spain
| | - Guillermo Sanz
- Blood Bank, Hematology Service. Hospital Universitari I Politècnic La Fe, Valencia, Spain
| | - Miguel Angel Sanz
- Blood Bank, Hematology Service. Hospital Universitari I Politècnic La Fe, Valencia, Spain
| | - Nelly Carpio
- Blood Bank, Hematology Service. Hospital Universitari I Politècnic La Fe, Valencia, Spain
| | | |
Collapse
|
17
|
Martínez García L, Pardo-Hernández H, Sanabria AJ, Alonso-Coello P, Penman K, McFarlane E, Martínez García L, Pardo-Hernández H, Sanabria A, Alonso-Coello P, Penman K, McFarlane E, Blanchard S, Brereton L, Browers M, Dean V, Flórez Gómez I, Fuentes C, Grimmer K, Harris J, Haynes C, Iorio A, James R, Kwong J, Lynch R, Nolan K, Ogunremi T, Okechukwu K, Prabhu Iyer N, Qaseem A, Rey M, Schorr S, Selva A, Shaw B, Shearn P, Shin E, Stapon C, Tam I, Thornton J, Uhl S, Vandvik P, Vernooij R. Guideline on terminology and definitions of updating clinical guidelines: The Updating Glossary. J Clin Epidemiol 2018; 95:28-33. [DOI: 10.1016/j.jclinepi.2017.11.023] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2017] [Revised: 11/08/2017] [Accepted: 11/28/2017] [Indexed: 11/30/2022]
|
18
|
Abstract
Purpose To examine distraction-based methods for treatment of early onset scoliosis (EOS), focusing on the magnetically controlled growing rod system (MCGR) relative to traditional growing rod system (TGR). To briefly discuss internal magnetically controlled nails for bone lengthening as another application of magnetic growth modulation. Results Relative to TGR, MCGR involves fewer complications related to infection and general anesthesia because of fewer successive surgeries required. Further, MCGR accounts for better psychosocial patient outcome and potentially a lower long-term cost, mainly because of shortened periods of hospitalization. Intramedullary lengthening nails involve fewer complications compared to internal limb lengthening devices related to infections, nerve damage, shortening, improper healing, stiffness, and scarring. Intramedullary lengthening nails appear to alleviate psychosocial burden of patients especially when compared to external fixators. Conclusions Although the current gold standard for treating some types of early onset scoliosis (EOS) is the traditional growing rod system, the magnetically controlled growing rod (MCGR) system is an alternative method for treating EOS. MCGR is promising in that it involves less surgical procedures, shorter hospital stays, and lower long-term cost relative to TGR. Similarly, the use of magnetically controlled intramedullary lengthening nails is a promising alternative to the Ilizarov method for limb lengthening.
Collapse
|
19
|
Abstract
Purpose: Informal caregivers of bedridden elders need a respite. One form of obtaining a respite is through volunteers who are contacted by means of information and communication technology (ICT). Method: A qualitative study was carried out in a low-income district in Santiago, Chile, to learn about how caregivers of bedridden elders perceive the possibility of using ICT to access this respite. In-depth interviews were carried out and transcribed verbatim, then analysed using open coding. Results: The results reveal that caregivers are willing to receive a volunteer in their home and use ICT to communicate with them, although a discrepancy exists between the use of devices connected to the Internet and feature phones. Conclusion: This study concludes that informal caregivers of bedridden elders have a favourable disposition towards accessing a respite system by means of ICT based on a peer-to-peer economy.
Collapse
Affiliation(s)
- Esmeralda Abarca
- a School of Nursing , Pontificia Universidad Católica de Chile , Santiago , Chile
| | - Solange Campos
- a School of Nursing , Pontificia Universidad Católica de Chile , Santiago , Chile
| | - Valeria Herskovic
- b Department of Computer Science, Pontificia Universidad Católica de Chile Carolina Fuentes, School of Computer Science , University of Nottingham , Nottingham , United Kingdom
| | - Carolina Fuentes
- c School of Computer Science , University of Nottingham , Nottingham , United Kingdom
| |
Collapse
|
20
|
Mukherjee B, Fuentes C, Lambert J. Out-of-field dosimetry and 2nd cancer risk assessment of child patients under proton therapy using a TLD-based microdosimeter. RADIAT MEAS 2017. [DOI: 10.1016/j.radmeas.2017.04.015] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
21
|
Rodríguez I, Herskovic V, Gerea C, Fuentes C, Rossel PO, Marques M, Campos M. Understanding Monitoring Technologies for Adults With Pain: Systematic Literature Review. J Med Internet Res 2017; 19:e364. [PMID: 29079550 PMCID: PMC5681725 DOI: 10.2196/jmir.7279] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2017] [Revised: 08/24/2017] [Accepted: 09/10/2017] [Indexed: 12/16/2022] Open
Abstract
BACKGROUND Monitoring of patients may decrease treatment costs and improve quality of care. Pain is the most common health problem that people seek help for in hospitals. Therefore, monitoring patients with pain may have significant impact in improving treatment. Several studies have studied factors affecting pain; however, no previous study has reviewed the contextual information that a monitoring system may capture to characterize a patient's situation. OBJECTIVE The objective of this study was to conduct a systematic review to (1) determine what types of technologies have been used to monitor adults with pain, and (2) construct a model of the context information that may be used to implement apps and devices aimed at monitoring adults with pain. METHODS A literature search (2005-2015) was conducted in electronic databases pertaining to medical and computer science literature (PubMed, Science Direct, ACM Digital Library, and IEEE Xplore) using a defined search string. Article selection was done through a process of removing duplicates, analyzing title and abstract, and then reviewing the full text of the article. RESULTS In the final analysis, 87 articles were included and 53 of them (61%) used technologies to collect contextual information. A total of 49 types of context information were found and a five-dimension (activity, identity, wellness, environment, physiological) model of context information to monitor adults with pain was proposed, expanding on a previous model. Most technological interfaces for pain monitoring were wearable, possibly because they can be used in more realistic contexts. Few studies focused on older adults, creating a relevant avenue of research on how to create devices for users that may have impaired cognitive skills or low digital literacy. CONCLUSIONS The design of monitoring devices and interfaces for adults with pain must deal with the challenge of selecting relevant contextual information to understand the user's situation, and not overburdening or inconveniencing users with information requests. A model of contextual information may be used by researchers to choose possible contextual information that may be monitored during studies on adults with pain.
Collapse
Affiliation(s)
- Iyubanit Rodríguez
- Department of Computer Science, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Valeria Herskovic
- Department of Computer Science, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Carmen Gerea
- Department of Computer Science, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Carolina Fuentes
- Department of Computer Science, Pontificia Universidad Católica de Chile, Santiago, Chile
- School of Computer Science, University of Nottingham, Nottingham, United Kingdom
| | - Pedro O Rossel
- Department of Computer Science, Universidad Católica de la Santísima Concepción, Concepción, Chile
| | - Maíra Marques
- Department of Computer Science, Universidad de Chile, Santiago, Chile
| | - Mauricio Campos
- Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile
| |
Collapse
|
22
|
Cavero T, Rabasco C, López A, Román E, Ávila A, Sevillano Á, Huerta A, Rojas-Rivera J, Fuentes C, Blasco M, Jarque A, García A, Mendizabal S, Gavela E, Macía M, Quintana LF, María Romera A, Borrego J, Arjona E, Espinosa M, Portolés J, Gracia-Iguacel C, González-Parra E, Aljama P, Morales E, Cao M, Rodríguez de Córdoba S, Praga M. Eculizumab in secondary atypical haemolytic uraemic syndrome. Nephrol Dial Transplant 2017; 32:466-474. [PMID: 28339660 PMCID: PMC5410989 DOI: 10.1093/ndt/gfw453] [Citation(s) in RCA: 101] [Impact Index Per Article: 14.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2016] [Accepted: 11/28/2016] [Indexed: 12/18/2022] Open
Abstract
Background. Complement dysregulation occurs in thrombotic microangiopathies (TMAs) other than primary atypical haemolytic uraemic syndrome (aHUS). A few of these patients have been reported previously to be successfully treated with eculizumab. Methods. We identified 29 patients with so-called secondary aHUS who had received eculizumab at 11 Spanish nephrology centres. Primary outcome was TMA resolution, defined by a normalization of platelet count (>150 × 109/L) and haemoglobin, disappearance of all the markers of microangiopathic haemolytic anaemia (MAHA), and improvement of renal function, with a ≥25% reduction of serum creatinine from the onset of eculizumab administration. Results. Twenty-nine patients with secondary aHUS (15 drug-induced, 8 associated with systemic diseases, 2 with postpartum, 2 with cancer-related, 1 associated with acute humoral rejection and 1 with intestinal lymphangiectasia) were included in this study. The reason to initiate eculizumab treatment was worsening of renal function and persistence of TMA despite treatment of the TMA cause and plasmapheresis. All patients showed severe MAHA and renal function impairment (14 requiring dialysis) prior to eculizumab treatment and 11 presented severe extrarenal manifestations. A rapid resolution of the TMA was observed in 20 patients (68%), 15 of them showing a ≥50% serum creatinine reduction at the last follow-up. Comprehensive genetic and molecular studies in 22 patients identified complement pathogenic variants in only 2 patients. With these two exceptions, eculizumab was discontinued, after a median of 8 weeks of treatment, without the occurrence of aHUS relapses. Conclusion. Short treatment with eculizumab can result in a rapid improvement of patients with secondary aHUS in whom TMA has persisted and renal function worsened despite treatment of the TMA-inducing condition.
Collapse
Affiliation(s)
- Teresa Cavero
- Department of Nephrology, Instituto de Investigación Hospital 12 de Octubre (imas12), Madrid, Spain
| | - Cristina Rabasco
- Department of Nephrology, University Hospital Reina Sofía, Córdoba, Spain
| | - Antía López
- Department of Nephrology, University Hospital A Coruña, A Coruña, Spain
| | - Elena Román
- Department of Pediatric Nephrology, University Hospital La Fe, Valencia, Spain
| | - Ana Ávila
- Department of Nephrology, University Hospital Dr Peset, Valencia, Spain
| | - Ángel Sevillano
- Department of Nephrology, Instituto de Investigación Hospital 12 de Octubre (imas12), Madrid, Spain
| | - Ana Huerta
- Department of Nephrology, University Hospital Puerta de Hierro, Madrid, Spain
| | - Jorge Rojas-Rivera
- Department of Nephrology, University Hospital Fundación Jiménez Díaz, Madrid, Spain
| | - Carolina Fuentes
- Department of Hematology, University Hospital La Fe, Valencia, Spain
| | - Miquel Blasco
- Department of Nephrology, University Hospital Clinic, Barcelona, Spain
| | - Ana Jarque
- Department of Nephrology, University Hospital Nuestra Señora de La Candelaria, Santa Cruz de Tenerife, Spain
| | - Alba García
- Department of Nephrology, University Hospital A Coruña, A Coruña, Spain
| | - Santiago Mendizabal
- Department of Pediatric Nephrology, University Hospital La Fe, Valencia, Spain
| | - Eva Gavela
- Department of Nephrology, University Hospital Dr Peset, Valencia, Spain
| | - Manuel Macía
- Department of Nephrology, University Hospital Nuestra Señora de La Candelaria, Santa Cruz de Tenerife, Spain
| | - Luis F Quintana
- Department of Nephrology, University Hospital Clinic, Barcelona, Spain
| | - Ana María Romera
- Department of Nephrology, University Hospital de Ciudad Real, Ciudad Real, Spain
| | - Josefa Borrego
- Department of Nephrology, University Hospital de Jaén, Jaén, Spain
| | - Emi Arjona
- Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas, Madrid and Centro de Investigación Biomédica en Red en Enfermedades Raras, Madrid, Spain
| | - Mario Espinosa
- Department of Nephrology, University Hospital Reina Sofía, Córdoba, Spain
| | - José Portolés
- Department of Nephrology, University Hospital Puerta de Hierro, Madrid, Spain
| | | | | | - Pedro Aljama
- Department of Nephrology, University Hospital Reina Sofía, Córdoba, Spain
| | - Enrique Morales
- Department of Nephrology, Instituto de Investigación Hospital 12 de Octubre (imas12), Madrid, Spain
| | - Mercedes Cao
- Department of Nephrology, University Hospital A Coruña, A Coruña, Spain
| | - Santiago Rodríguez de Córdoba
- Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas, Madrid and Centro de Investigación Biomédica en Red en Enfermedades Raras, Madrid, Spain
| | - Manuel Praga
- Department of Nephrology, Instituto de Investigación Hospital 12 de Octubre (imas12), Madrid, Spain.,Department of Pediatric Nephrology, University Hospital La Fe, Valencia, Spain
| |
Collapse
|
23
|
Corvetto MA, Pedemonte JC, Varas D, Fuentes C, Altermatt FR. Simulation-based training program with deliberate practice for ultrasound-guided jugular central venous catheter placement. Acta Anaesthesiol Scand 2017; 61:1184-1191. [PMID: 28685812 DOI: 10.1111/aas.12937] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2016] [Revised: 06/06/2017] [Accepted: 06/17/2017] [Indexed: 12/20/2022]
Abstract
BACKGROUND Current evidence supports the utility of simulation training for bedside procedures such as ultrasound-guided jugular central venous catheter (CVC) insertion. However, a standardized methodology to teach procedural skills has not been determined yet. The aim of this study was to evaluate the effectiveness of a simulation-based training program for improving novice technical performance during ultrasound-guided internal jugular CVC placement. METHODS Postgraduate year 1 (PGY-1) residents from anesthesiology, emergency medicine, cardiology, ICU, and nephrology specialties were trained in four deliberate practice sessions. Learning objectives included principles of ultrasound (US), preparation (gown, glove, draping), procedural skills I (US scanning and puncture), and procedural skills II (catheter insertion). CVC technical proficiency was tested pre- and post-training using hand-motion analysis with the Imperial College Surgical Assessment Device (ICSAD) and a global rating scale (GRS). RESULTS Thirty-five PGY-1 residents successfully completed the program. These novices' GRS scores improved significantly after the training (P < 0.001). Total path length measured with the ICSAD decreased significantly after the training (P = 0.008). Procedural time decreased significantly after training from 387 (310-501) seconds to 200 (157-261) seconds (median and interquartile range) (P = 0.029). CONCLUSION This simulation-training program based on deliberate practice significantly increased the technical skills of residents in US-guided short-axis, out-of-plane internal jugular CVC placement. Data also confirm the validity of the ICSAD as an assessment tool for ultrasound-guided internal jugular CVC placement learning.
Collapse
Affiliation(s)
- M. A. Corvetto
- Department of Anesthesiology; School of Medicine; Pontificia Universidad Catolica de Chile; Santiago Chile
| | - J. C. Pedemonte
- Department of Anesthesiology; School of Medicine; Pontificia Universidad Catolica de Chile; Santiago Chile
| | - D. Varas
- Department of Anesthesiology; School of Medicine; Pontificia Universidad Catolica de Chile; Santiago Chile
| | - C. Fuentes
- Department of Anesthesiology; School of Medicine; Pontificia Universidad Catolica de Chile; Santiago Chile
| | - F. R. Altermatt
- Department of Anesthesiology; School of Medicine; Pontificia Universidad Catolica de Chile; Santiago Chile
| |
Collapse
|
24
|
Melnikov AV, Alonso A, Ascasíbar E, Balbin R, Chmyga AA, Dnestrovskij YN, Eliseev LG, Estrada T, Fontdecaba JM, Fuentes C, Guasp J, Herranz J, Hidalgo C, Komarov AD, Kozachek AS, Krupnik LI, Liniers M, Lysenk SE, Mccarthy KJ, Ochando MA, Pastor I, De Pablos JL, Pedrosa MA, Perfilov SV, Petrov SY, Tereshin VI. Plasma Potential Evolution Study by HIBP Diagnostic During NBI Experiments in the TJ-II Stellarator. Fusion Science and Technology 2017. [DOI: 10.13182/fst07-a1284] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- A. V. Melnikov
- Russian Research Centre ‘Kurchatov Institute’, Nuclear Fusion Institute, 123182 Moscow, Russia
| | - A. Alonso
- Laboratorio Nacional de Fusión por Confinamiento Magnético Asociación EURATOM-CIEMAT, 28040-Madrid, Spain
| | - E. Ascasíbar
- Laboratorio Nacional de Fusión por Confinamiento Magnético Asociación EURATOM-CIEMAT, 28040-Madrid, Spain
| | - R. Balbin
- Laboratorio Nacional de Fusión por Confinamiento Magnético Asociación EURATOM-CIEMAT, 28040-Madrid, Spain
| | - A. A. Chmyga
- National Science Center, Kharkov Institute of Physics and Technology, Institute of Plasma Physics, NSC KIPT 61108 Kharkov, Ukraine
| | - Yu. N. Dnestrovskij
- Russian Research Centre ‘Kurchatov Institute’, Nuclear Fusion Institute, 123182 Moscow, Russia
| | - L. G. Eliseev
- Russian Research Centre ‘Kurchatov Institute’, Nuclear Fusion Institute, 123182 Moscow, Russia
| | - T. Estrada
- Laboratorio Nacional de Fusión por Confinamiento Magnético Asociación EURATOM-CIEMAT, 28040-Madrid, Spain
| | - J. M. Fontdecaba
- Laboratorio Nacional de Fusión por Confinamiento Magnético Asociación EURATOM-CIEMAT, 28040-Madrid, Spain
| | - C. Fuentes
- Laboratorio Nacional de Fusión por Confinamiento Magnético Asociación EURATOM-CIEMAT, 28040-Madrid, Spain
| | - J. Guasp
- Laboratorio Nacional de Fusión por Confinamiento Magnético Asociación EURATOM-CIEMAT, 28040-Madrid, Spain
| | - J. Herranz
- Laboratorio Nacional de Fusión por Confinamiento Magnético Asociación EURATOM-CIEMAT, 28040-Madrid, Spain
| | - C. Hidalgo
- Laboratorio Nacional de Fusión por Confinamiento Magnético Asociación EURATOM-CIEMAT, 28040-Madrid, Spain
| | - A. D. Komarov
- National Science Center, Kharkov Institute of Physics and Technology, Institute of Plasma Physics, NSC KIPT 61108 Kharkov, Ukraine
| | - A. S. Kozachek
- National Science Center, Kharkov Institute of Physics and Technology, Institute of Plasma Physics, NSC KIPT 61108 Kharkov, Ukraine
| | - L. I. Krupnik
- National Science Center, Kharkov Institute of Physics and Technology, Institute of Plasma Physics, NSC KIPT 61108 Kharkov, Ukraine
| | - M. Liniers
- Laboratorio Nacional de Fusión por Confinamiento Magnético Asociación EURATOM-CIEMAT, 28040-Madrid, Spain
| | - S. E. Lysenk
- Russian Research Centre ‘Kurchatov Institute’, Nuclear Fusion Institute, 123182 Moscow, Russia
| | - K. J. Mccarthy
- Laboratorio Nacional de Fusión por Confinamiento Magnético Asociación EURATOM-CIEMAT, 28040-Madrid, Spain
| | - M. A. Ochando
- Laboratorio Nacional de Fusión por Confinamiento Magnético Asociación EURATOM-CIEMAT, 28040-Madrid, Spain
| | - I Pastor
- Laboratorio Nacional de Fusión por Confinamiento Magnético Asociación EURATOM-CIEMAT, 28040-Madrid, Spain
| | - J. L. De Pablos
- Laboratorio Nacional de Fusión por Confinamiento Magnético Asociación EURATOM-CIEMAT, 28040-Madrid, Spain
| | - M. A. Pedrosa
- Laboratorio Nacional de Fusión por Confinamiento Magnético Asociación EURATOM-CIEMAT, 28040-Madrid, Spain
| | - S. V. Perfilov
- Russian Research Centre ‘Kurchatov Institute’, Nuclear Fusion Institute, 123182 Moscow, Russia
| | - S. Ya. Petrov
- A. F. Ioffe Physical-Technical Institute, St. Petersburg, Russia
| | - V. I. Tereshin
- National Science Center, Kharkov Institute of Physics and Technology, Institute of Plasma Physics, NSC KIPT 61108 Kharkov, Ukraine
| | | |
Collapse
|
25
|
Cozzi G, Gottardo F, Brscic M, Contiero B, Irrgang N, Knierim U, Pentelescu O, Windig J, Mirabito L, Kling Eveillard F, Dockes A, Veissier I, Velarde A, Fuentes C, Dalmau A, Winckler C. Dehorning of cattle in the EU Member States: A quantitative survey of the current practices. Livest Sci 2015. [DOI: 10.1016/j.livsci.2015.05.011] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
26
|
García M, Peña J, Villamil S, Fuentes C, Martín J, Martínez J, Hernández R, Armijo A, Borque C, Espiñeira M. Radiotherapy in Ledderhose's disease. Rep Pract Oncol Radiother 2013. [DOI: 10.1016/j.rpor.2013.03.395] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
27
|
Álvarez P, Fuentes C, García N, Modesto V. Evaluation of the duration of the antibiotic prophylaxis in paediatric postoperative heart surgery patients. Pediatr Cardiol 2012; 33:735-8. [PMID: 22349725 DOI: 10.1007/s00246-012-0202-2] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/20/2011] [Accepted: 11/23/2011] [Indexed: 11/28/2022]
Abstract
The ideal duration of postoperative antibiotic prophylaxis in heart surgery is unknown. The most recent guidelines recommend a decrease in prophylaxis time to decrease the emergence of multiresistant germs. However, compliance with these recommendations is scant. Our aim was to determine whether a decrease in prophylaxis time entails an increase in the infection rate. A retrospective study was performed between September 2003 and March 2006, including all patients of ages between 1 day and 14 years who were admitted to the intensive care unit after heart surgery. Patients being treated for an infection at the time of surgery were excluded. The appearance of nosocomial infection, localisation, and the causative agent, if isolated, were included; demographic and clinical analytical variables, duration and type of antibiotic prophylaxis, and duration of other invasive devices were also included. Standard analysis and multivariable logistical regression were performed. 194 patients were included in the study. The median duration of antibiotic prophylaxis was 72 h (range 24 to 176), with the most-used prophylaxis regimen being second-generation cephalosporins plus aminoglycosides. The incidence of nosocomial infection, mainly bacteraemia, was 11.9%. The type of antibiotic therapy used for prophylaxis did not affect the incidence of infection. In the multivariable logistical regression, only prolongation of antibiotic prophylaxis >48 h, central venous access maintenance time, and intubation increased the infection rate. The suspension of antibiotic prophylaxis in the 48 h after surgery in pediatric patients undergoing heart surgery does not increase the incidence of nosocomial infection. According to our results, prolongation of prophylaxis >48 h increases the infection rate.
Collapse
Affiliation(s)
- Pablo Álvarez
- Pediatric Intensive Care Unit, Hospital La Fe, Valencia, Spain.
| | | | | | | |
Collapse
|
28
|
Lloret M, Martínez J, Carmona-Vigo R, Cabrera R, Fuentes C, Lara P. PO-0712 HYPERFRACTIONATED RADIOTHERAPY WITH CONCURRENT CHEMOTHERAPY AND CETUXIMAB IN FAR ADVANCED HEAD AND NECK CANCER. Radiother Oncol 2012. [DOI: 10.1016/s0167-8140(12)71045-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
29
|
Moore C, Fuentes C, Sauma D, Morales J, Bono MR, Rosemblatt M, Fierro JA. Retinoic acid generates regulatory T cells in experimental transplantation. Transplant Proc 2012; 43:2334-7. [PMID: 21839265 DOI: 10.1016/j.transproceed.2011.06.057] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Regulatory T cells play a key role to inhibit effector lymphocytes, avoid, autoimmunity, and restrain allogeneic immunity. Retinoic acid is an important cofactor that stimulates the generation and expansion of regulatory T cells. Naive T cells, coincubated with allogeneic antigen-presenting cells and retinoic acid, in conjunction with transforming growth factor (TGF) β and interleukin (IL) 2, generated allogeneic regulatory T cells de novo. These cells were able to inhibit skin rejection in adoptive transfer experiments. The generation of regulatory T cells ex vivo with retinoic acid, TGF-β, and IL-2 represents a new step toward specific regulation of allogeneic immune responses.
Collapse
Affiliation(s)
- C Moore
- Facultad de Ciencias Biológicas, Universidad Andrés Bello, Santiago, Chile
| | | | | | | | | | | | | |
Collapse
|
30
|
Tansel B, Fuentes C, Sanchez M, Predoi K, Acevedo M. Persistence profile of polyaromatic hydrocarbons in shallow and deep Gulf waters and sediments: effect of water temperature and sediment-water partitioning characteristics. Mar Pollut Bull 2011; 62:2659-2665. [PMID: 22018883 DOI: 10.1016/j.marpolbul.2011.09.026] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/25/2011] [Revised: 09/19/2011] [Accepted: 09/21/2011] [Indexed: 05/31/2023]
Abstract
Persistence profiles of selected polyaromatic hydrocarbons (PAHs) were analyzed depending on temperature variations in the water column and water-sediment interactions in the Gulf of Mexico. The PAHs studied include anthracene, fluoranthene, pyrene, and chrysene. The half-lives of PAHs in the deep waters (over 1000 m) are about twice as long as those in the shallow areas (100-150 m), and almost 2.5 times as long as those in the top layer (0-10 m) of the water column. The half-lives of the PAHs in the sediments are significantly longer. Among the PAHs studied, chrysene is the most persistent in the water column, and pyrene is the most persistent in the sediments. The half-life of chrysene in the shallow and deep waters is over 2.5 and about 5 years, respectively. For pyrene, the half-life in the shallow and deep sediments is about 9 and 16 years, respectively.
Collapse
Affiliation(s)
- B Tansel
- Department of Civil and Environmental Engineering, Florida International University, Miami, FL 33174, USA.
| | | | | | | | | |
Collapse
|
31
|
Zaidi H, Fuentes C, El Naqa I. SU-GG-I-102: Comparative Methods for PET Image Segmentation in Pharyngolaryngeal Squamous Cell Carcinoma. Med Phys 2010. [DOI: 10.1118/1.3468135] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
32
|
Elgueta S, Fuentes C, Arenas A, Labraña C, Gajardo J, Lopez M, Hernandez J, Rodriguez H, Rodriguez L. Evaluation of the Stages Involved in Cold Ischemia Time in Renal Transplants in Chile. Transplant Proc 2010; 42:248-9. [DOI: 10.1016/j.transproceed.2009.11.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
33
|
Escobar B, Estévez AM, Fuentes C, Venegas D. [Use of algarrobo (Prosopis chilensis (Mol) Stuntz) flour as protein and dietary fiber source in cookies and fried chips manufacture]. Arch Latinoam Nutr 2009; 59:191-198. [PMID: 19719017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
Limiting amino acids of the protein from chilean "algarrobo" are isoleucine, theronine and methionine/cyteine. Cereals and legume blends allow to improve the amino acid balance, since legume have more lysine, and cereals are richer in sulphur amino acids. Due to the nutritional interest of "algarrobo" cotyledons, the use of "algarrobo cotyledon" flour (ACF) in sweet and salty snack manufacture was evaluated. Cookies and fried salty chips with 0%, 10% and 20% ACF were prepared. Flours were analyzed for color, particle size, moisture, proximate composition, available lysine, and soluble, insoluble and total dietary fiber. Cookies and chips were analyzed for the same characteristics (except for particle size); besides there were determined water activity, weight and size of the units, and also, the caloric value was computed. Sensory quality and acceptance of both products were evaluated. It is noticeable the high amount of protein, lipids, ash, crude fiber (63.6; 10.2; 4.3 and 4.2 g/100 g dmb, respectively), available lysine (62.4 mg/g protein) and total dietary fiber (24.2 g/100 g dmb) of ACF. Both, cookies and chips with ACF, showed a significant increase in the amount of protein, lipids, ash, crude fiber and, available lysine (from 15.5 to 19,3 and from 20.3 a 29.6 mg lisina/g protein, respectively), and total dietary fiber (from 1.39 to 2.80 and from 1.60 a 5.60 g/100 g dmb, respectively). All of the cookies trials were well accepted ("I like it very much"); chips with 10% of AFC showed the highest acceptance ("I like it"). It can be concluded that the use of ACF in cookies and chips manufacture increases the contribution of available lysine; their protein and dietary fiber content, improving the soluble/insoluble fiber ratio, without affect neither their physical nor their sensory acceptance.
Collapse
Affiliation(s)
- Berta Escobar
- Departamento de Agroindustria y Enología, Facultad de Ciencias Agronómicas, Universidad de Chile, Santiago Chile
| | | | | | | |
Collapse
|
34
|
Cobo M, Delgado R, Gil S, Herruzo I, Baena V, Carabante F, Moreno P, Ruiz JL, Bretón JJ, Del Rosal JM, Fuentes C, Moreno P, García E, Villar E, Contreras J, Alés I, Benavides M. Conservative treatment with transurethral resection, neoadjuvant chemotherapy followed by radiochemotherapy in stage T2-3 transitional bladder cancer. Clin Transl Oncol 2009; 8:903-11. [PMID: 17169764 DOI: 10.1007/s12094-006-0154-1] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
PURPOSE Organ preservation has been investigated in patients (p) with infiltrating transitional cell carcinoma (TCC) of the bladder over the past decade as an alternative to radical cystectomy. This is a trimodal schedule study, including transurethral resection of bladder tumor (TURB), neoadjuvant chemotherapy and concomitant radiochemotherapy (RTC). PATIENTS AND METHODS From April 1996 until August 2005, 29 evaluable patients (p) with T2-T3NXM0 bladder cancer were enrolled. After a transurethral resection of bladder tumor (TURB), we administered 2 cycles of induction chemotherapy with CMV (15 p) or Gemcitabine-Cisplatin (14 p) followed by radiotherapy 45 Gy 1.8 Gy/fraction and two cycles of concomitant cisplatin 70 mg/m(2). 2-3 weeks later, a cystoscopy with tumor-site biopsy was performed. If complete histological response, p were treated with consolidation radiotherapy until 64.8 Gy. For p with residual or recurrent tumor, cystectomy was performed. RESULTS We included 28 men and 1 women (median age 63, range 39-72 years) with PS (ECOG) 0-1. The stage was: 21 p T2; 6 p T3a; and 2 p T3b. Toxicity was higher in CMV compared with Gem- Cis: grade (3/4) neutropenia 4/15 (26%) vs 1/14 (7%); febrile neutropenia 3/15 (20%) vs 1/14 (7%); grade (3/4) trombocytopenia 2/15 (13%) vs 1/14 (7%). Toxicities with concomitant RCT were low-moderate: urocystitis (26%) and enteritis (18%). RESPONSE microscopically complete TURB was obtained in 20 p (69%), but not in 9 p (31%) (7 microscopic, and 2 macroscopic residual tumor). We found a complete histologic response after induction RCT in 25 p (86%). After a median follow-up of 69.4 months (m) (range: 8-97.7), there were 8 deaths, with a overall survival of 72%. Furthermore 14 of 29 p (48%) were alive with intact bladder, and median survival time with intact bladder was 63.6 m (50.1-77.2); were predictive of best outcome T2 stage vs T3 (p < 0.0001), and complete histologic resection in initial TURB vs residual tumor (p = 0.0004). CONCLUSIONS Combined treatment provide high response rates and can be offered as an alternative option to radical cystectomy in selected patients with TCC. Patients with T2 stage and complete histologic resection in initial TURB had the best outcome.
Collapse
Affiliation(s)
- M Cobo
- Medical Oncology Section, Hospital Regional Universitario Carlos Haya, Málaga, Spain.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Fuentes C, Liniers M, Guasp J, Botija J, Doncel J, Sarasola X, Wolfers G, Alonso J, Carrasco R, Marcon G, Acedo M, Sanchez E, Weber M, Medrano M, Soleto A, Tera J, Ciric D. Power transmission of the neutral beam heating beams at TJ-II. Fusion Engineering and Design 2007. [DOI: 10.1016/j.fusengdes.2007.07.054] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
36
|
Liaño F, Felipe C, Tenorio MT, Rivera M, Abraira V, Sáez-de-Urturi JM, Ocaña J, Fuentes C, Severiano S. Long-term outcome of acute tubular necrosis: a contribution to its natural history. Kidney Int 2007; 71:679-86. [PMID: 17264879 DOI: 10.1038/sj.ki.5002086] [Citation(s) in RCA: 106] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
As long-term outcome studies of acute renal failure (ARF) are scarce and non-homogeneous, we studied 187 consecutive acute tubular necrosis (ATN) patients without previous nephropathies, discharged alive from our hospital between October 77 and December 92 and followed-up until December 99 (range 7-22 years; median 7.2). Variables were analyzed at the time of the acute episode and during follow-up. In 2000-2001 a clinical evaluation was made in 58 of the 82 patients still alive. Ten patients were lost to follow-up and 95 died. In 59% death was related with the disease present when the ATN developed. Kaplan-Meir survival curve showed 89, 67, 50, and 40% at 1, 5, 10, and 15 years, respectively, after discharge. Survival curves were significantly better (log-rank P<0.001) among the youngest, those surviving a polytrauma, those without comorbidity and surprisingly those treated in intensive care units. The proportional Cox model showed that age (hazard ratio (HR) 1.04 per year of age; P=0.000), presence of comorbid factors (HR 4.29; P=0.006), surgical admission (HR 0.45; P=0.000), and male sex (HR 1.72; P=0.020) were the variables associated with long-term follow-up. In the evaluated patients renal function was normal in 81%. Long-term outcome after ARF depends on absence of co-morbid factors, cause of initial admission and age. Although the late mortality rate is high and related with the original disease, renal function is adequate in most patients.
Collapse
Affiliation(s)
- F Liaño
- Nephrology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.
| | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Fuentes C, Menéndez E, Pineda J, Martínez De Esteban JP, Anda E, Goñi MJ, Bausch B, Neumann HPH. The malignant potential of a succinate dehydrogenase subunit B germline mutation. J Endocrinol Invest 2006; 29:350-2. [PMID: 16699302 DOI: 10.1007/bf03344107] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
Familial catecholamine secreting tumors have been associated with multiple endocrine neoplasia type 2, Von Hippel-Lindau disease and neurofibromatosis type 1. In the last years, mutations of genes encoding subunits B, C and D of the succinate dehydrogenase have been discovered as other causes of pheochromocytomas and paragangliomas. We diagnosed a malignant retroperitoneal paraganglioma in a 64-yr-old man with bone metastasis in 2001. Two years later a retroperitoneal benign paraganglioma was found and resected in his 32-yr-old daughter. Thus we diagnosed in this family a paraganglioma syndrome. We performed molecular genetic analyses of the genes SDHB, SDHC, and SDHD. We detected in the SDHB gene the mutation SDHB c. 558-3 C> G affecting the splice site of exon 5. In a second daughter the mutation was also detected, thorough clinical investigation revealed normal results. We conclude that the SDHB mutation predisposes to abdominal extra-adrenal and potential malignant pheochromocytoma with incomplete penetrance.
Collapse
Affiliation(s)
- C Fuentes
- Department of Endocrinology, Hospital de Navarra, Pamplona, Spain.
| | | | | | | | | | | | | | | |
Collapse
|
38
|
Forga L, Corbalán M, Marti A, Fuentes C, Martínez-González M, Martínez A. Influencia del polimorfismo -3826 A → G en el gen de la UCP1 sobre los componentes del síndrome metabólico. An Sist Sanit Navar 2003. [DOI: 10.4321/s1137-66272003000300005] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
39
|
Forga LL, Corbalán M, Marti A, Fuentes C, Martínez-González MA, Martínez A. [Influence of the polymorphism 03826 A --> G in the UCP1 gene on the components of metabolic syndrome]. An Sist Sanit Navar 2003; 26:231-6. [PMID: 12951617 DOI: 10.23938/assn.0449] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
BACKGROUND The uncoupling protein UCP1 has been related to the development and/or maintenance of obesity through its involvement in regulating energy balance. The role of this mitochondrial protein in humans is uncertain due to the scarce presence of the brown adipose tissue in the adult individual. The polymorphism -3826 A/G of the UCP1 alone or in conjunction with the mutation Trp64Arg of the adrenergic receptor b3 has been associated with obesity, diabetes mellitus and related diseases although with contradictory results. With the aim of determining the influence of polymorphism -3826 A/G of the UCP1 on the classical components of the metabolic syndrome in our population, we studied 159 obese individuals and 154 of normal weight, with a study design of cases and controls. In all of them Body Mass Index (BMI), hip/waist index, % of body fat, arterial tension (AT), lipidic profile, leptine, basal glucemia and basal insulinemia were determined. Similarly, the presence of the above mentioned mutation of the UCPI gene was analysed. RESULTS Significant differences were obtained in all of the variables studied between obese (cases) and normal weight (controls). Within the obese group, polymorphism -3826 A/G of the UCP1 gene (n=53) was associated with a greater BMI (p=0.03), greater percentage of body fat (p=0.04) and higher AT both systolic (p=0.009) and diastolic (p=0.02). There were no statistically significant differences in any of the other indices evaluated. CONCLUSION The fundamental factor that influences the components of the metabolic syndrome is obesity. However, the polymorphism -3826 A/G of the UCP1 gene is associated with a greater degree of obesity and very high figures of AT.
Collapse
Affiliation(s)
- L l Forga
- Servicio de Endocrinología, Hospital de Navarra, 31008 Pamplona, Spain.
| | | | | | | | | | | |
Collapse
|
40
|
Lafita J, Pineda J, Fuentes C, Martínez JP. [Secondary osteoporosis]. An Sist Sanit Navar 2003; 26 Suppl 3:53-62. [PMID: 14716358] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/28/2023]
Abstract
Secondary osteoporosis is caused by pathologies or medications, differing from the bone loss explainable by the post-menopausal stage or by ageing. The possible pathologies that can condition the loss of bone mass are very varied: endocrinological, digestive, genetic, haematological, rheumatic, post-transplant, pharmacological and a wide miscellaneous group. This article essentially reviews the endocrinological causes, with special emphasis on the more controversial aspects, followed by a clinical approach for the systematic diagnosis of these pathologies, which are frequent in cases initially labelled as primary osteoporosis
Collapse
Affiliation(s)
- J Lafita
- Servicio de Endocrinología, Centro de Consultas externas Príncipe de Viana, Pamplona, 31008, Spain
| | | | | | | |
Collapse
|
41
|
Lafita J, Pineda J, Fuentes C, Martínez JP. Osteoporosis secundarias. An Sist Sanit Navar 2003. [DOI: 10.4321/s1137-66272003000600005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
42
|
Martinez J, Villar A, Perez M, Fuentes C, Espineira M, Borque C, Hernandez R. Feasibility study on twice-a-day fractionated subcutaneous amifostine. Int J Radiat Oncol Biol Phys 2002. [DOI: 10.1016/s0360-3016(02)03598-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
43
|
Ascası́bar E, Alejaldre C, Alonso J, Almoguera L, Baciero A, Balbı́n R, Blaumoser M, Botija J, Brañas B, de la Cal E, Cappa A, Castellano J, Carrasco R, Castejón F, Cepero J, Cremy C, Doncel J, Eguilior S, Estrada T, Fernández A, Fuentes C, Garcı́a A, Garcı́a-Cortés I, Guasp J, Herranz J, Hidalgo C, Jiménez J, Kirpitchev I, Krivenski V, Labrador I, Lapayese F, Likin K, Liniers M, López-Fraguas A, López-Sánchez A, de la Luna E, Martı́n R, Martı́nez-Laso L, Medrano M, Méndez P, McCarthy K, Medina F, van Milligen B, Ochando M, Pacios L, Pastor I, Pedrosa M, de la Peña A, Portas A, Qin J, Rodrı́guez-Rodrigo L, Romero J, Salas A, Sánchez E, Sánchez J, Tabarés F, Tafalla D, Tribaldos V, Vega J, Zurro B. Overview of TJ-II flexible heliac results. Fusion Engineering and Design 2001. [DOI: 10.1016/s0920-3796(01)00237-x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
44
|
Fuentes C, Blaumoser M, Botija J, Ciric D, Guasp J, Liniers M, Salito A, Schedler B. Development and tests of B4C-covered heat shields for TJ-II. Fusion Engineering and Design 2001. [DOI: 10.1016/s0920-3796(01)00320-9] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
45
|
Martinez JC, Villar A, Cabezon MA, de Serdio JL, Fuentes C, Espiñeira M, Perez MD, Gil J, Artazkoz JJ, Borque C, Suñer M, Saavedra JA. Hyperfractionated chemoradiation with carbogen breathing, with or without erythropoietin: a stepwise developed treatment schedule for advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001; 50:47-53. [PMID: 11316545 DOI: 10.1016/s0360-3016(00)01526-1] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
PURPOSE To investigate the influence of carbogen breathing on chemoradiation and the effects of erythropoietin on transfusions. METHODS AND MATERIALS From March 1996 to April 2000, 42 (4 Stage III and 38 Stage IV) patients with head and neck cancer were treated with a twice-a-day hyperfractionated schedule. Each fraction consisted of 5 mg/m(2) of carboplatin plus 115 cGy with carbogen breathing. Treatment was given 5 days per week up to total doses of 350 mg/m(2) of carboplatin plus 8050 cGy in 7 weeks. Anemia was treated either by transfusion or by erythropoietin. RESULTS Forty-one patients tolerated the treatment as scheduled. All patients tolerated the planned radiation dose. Five transfusions were given in the first group, but no transfusion was needed in the erythropoietin group. Local toxicities remained at the level expected with irradiation alone. Chemotherapy toxicity was moderate. Forty-two complete responses were achieved. At two years actuarial local control, cause-specific survival and overall survival are respectively 85%, 69%, and 68%. At four years estimated probabilities of local control, cause-specific survival and overall survival are also 85%, 69%, and 68%. CONCLUSIONS These results compare favorably with those of most reported studies. The addition of carbogen breathing appears to improve the results of chemoradiation alone. Erythropoietin therapy avoided transfusions.
Collapse
Affiliation(s)
- J C Martinez
- Servicio de Oncologia Radioterapica, Hospital Nuestra Señora de la Candelaria, Carretera del Rosario s/n, 38010 Santa Cruz de Tenerife, Spain
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
|
47
|
Martinez J, Cabezon M, Fuentes C, Espiñeira M, Perez M, Serdio J, Artazkoz J, Gil J, Borque C, Villar A. 2193 Hyperfractionated chemoradiotherapy with carbogen breathing for advanced cancer of the head and neck. Int J Radiat Oncol Biol Phys 1999. [DOI: 10.1016/s0360-3016(99)90462-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
48
|
de Serdio JL, Villar A, Martinez JC, Perez MD, Martin JJ, Fuentes C, Gil-Curbelo J, Hernandez R, Suñer M, Espiñeira M, Artazkoz JJ, Saavedra JA. Chemotherapy as a part of each treatment fraction in a twice-a-day hyperfractionated schedule: a new chemoradiotherapy approach for advanced head and neck cancer. Head Neck 1998; 20:489-96. [PMID: 9702534 DOI: 10.1002/(sici)1097-0347(199809)20:6<489::aid-hed1>3.0.co;2-f] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
BACKGROUND Using chemotherapy as a part of each treatment fraction remains unexplored. This study integrates the concomitant administration of carboplatin with hyperfractionated irradiation by optimizing chemopotentiation through carboplatin administration with each irradiation fraction. METHODS From February 1993 to August 1996, 52 patients with advanced head and neck cancer were treated on a twice-a-day chemoradiotherapy schedule. Each fraction consisted of 115 cGy preceded by 5 mg/m2 of carboplatin. Treatment was given 5 days a week up to total doses of 350 mg/m2 of carboplatin + 8050 cGy in 7 weeks. RESULTS All (100%) of patients tolerated the treatment (83% as scheduled). Acute and late toxicities were moderate. Rates of 96% complete response (CR) and 4% partial response (PR) were achieved. At 52 months, local control and cause-specific survival rates are 72% and 59%, respectively. Nodal control rate is 95%. CONCLUSION These results show potential for improvement upon hyperfractionated radiotherapy alone and compare favorably with those of most reported trials.
Collapse
Affiliation(s)
- J L de Serdio
- Servicio de Otorrinolaringologia, Hospital de la Candelaria, Santa Cruz de Tenerife, Spain
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Torres-Alvarez B, Baranda L, Fuentes C, Delgado C, Santos-Martinez L, Portales-Perez D, Moncada B, Gonzalez-Amaro R. An immunohistochemical study of UV-induced skin lesions in actinic prurigo. Resistance of langerhans cells to UV light. Eur J Dermatol 1998; 8:24-8. [PMID: 9649710] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Actinic prurigo is an inflammatory disease of the skin that appears to be mediated by an abnormal immune response. Cell adhesion molecules play a key role in the induction of the immune response as well as in the pathogenesis of inflammation. We investigated the expression of cell adhesion and activation molecules, as well as the density of Langerhans cells in skin from patients with actinic prurigo. Skin biopsies from ultraviolet light-induced lesions, and non-irradiated areas from 10 actinic prurigo patients were studied; in addition, several spontaneous skin lesions were studied. Skin biopsies from normal individuals were used as controls. The expression of ICAM-1, ICAM-3, LFA-3, CD2, LFA-1, VLA-4, CD1a, VCAM-1, CD69, and activated b1 integrins were assessed by immunostaining. An increased expression of LFA-1, LFA-2, ICAM-3, VLA-4, and activated b1 integrins was observed in the cell infiltrate of actinic prurigo lesions and an up-regulated expression of ICAM-1 was detected in keratinocytes from these specimens. Interestingly, the number of Langerhans cells (CD1a + ) in actinic prurigo skin was not significantly affected by ultraviolet irradiation, a phenomenon that was not observed in normal controls. The increased expression of adhesion molecules in the cell infiltrate of actinic prurigo, indicates that these cells are activated and suggests that they are involved in the skin damage seen in these patients. The resistance of Langerhans cells from patients with actinic prurigo to ultraviolet light may have an important role in the pathogenesis of this condition. The involvement of keratinocytes in the pathogenesis of actinic prurigo is suggested by the expression of ICAM-1 on these cells.
Collapse
Affiliation(s)
- B Torres-Alvarez
- Department of Immunology, School of Medicine, University of San Luis Potosi, av. V.-Carranza 2405, 78210 San Luis Potosi, SLP, Mexico
| | | | | | | | | | | | | | | |
Collapse
|
50
|
Villar A, Martinez J, de Serdio L, Perez M, Fuentes C, Espiñeira E, Gil-Curbelo J, Cejas L, Hernandez R, Saavedra J. Carboplatin as part of each fraction of treatment: Potential for improvement upon hyperfractionated irradiation in advanced head and neck cancer. Eur J Cancer 1997. [DOI: 10.1016/s0959-8049(97)85508-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|